5 July 2022

T cells are immune cells that are key for the defense against pathogens and cancer. T cells depend on the membrane protein CD45 to initiate T cell receptor signaling, but how CD45 is controlled at the molecular level is poorly understood.

Vera Dunlock et al. (Dept. Tumor Immunology, research team of  Annemiek van Spriel) discovered that CD45 is tightly controlled by tetraspanin protein CD53 at the cell surface of T cells. Using a combination of genetic experiments, advanced microscopy, and in vivo models, they demonstrate that CD53 is a key regulator of CD45 activity required for T cell immunity. T cells lacking CD53 were defective in cell division, interferon production and tumor rejection. These findings reveal a novel mechanism for the regulation of T cell signaling that provides valuable insight into T cell biology and immunological memory formation. This has import consequences for understanding immunity to cancer and infectious diseases.

Tetraspanin CD53 controls T cell immunity through regulation of CD45RO stability, mobility, and function. Cell Rep. 2022 Jun 28;39(13):111006. doi: 10.1016/j.celrep.2022.111006. PMID: 35767951

Vera-Marie E. Dunlock, Abbey B. Arp, Simar Pal Singh, Stéphanie Charrin, Viet Nguyen, Erik Jansen, Fleur Schaper, Martin Ter Beest, Malou Zuidscherwoude, Sjoerd J. van Deventer, Britt Nakken, Peter Szodoray, Maria C. Demaria, Mark D. Wright, Laia Querol Cano, Eric Rubinstein, Annemiek B. van Spriel.



Related news items

A single protein complex balances the very first lineage decision of cells in human: towards foetus or placenta

21 June 2022 The international group of researchers spearheaded by Dick Zijlmans and Hendrik Marks together with colleagues from KU Leuven, examined which proteins are associated with the chromatin and how this affects gene transcription. read more

Dutch Society of Clinical Chemistry Science & Innovation Award for the team of Hans Jacobs

14 June 2022 The team of Hans Jacobs pioneers on the development of personalized diagnostics to measure minimal residual disease in patients with multiple myeloma. read more

European grants for groundbreaking Radboudumc research Professors Roshan Cools and Peter Friedl receive ERC Advanced Grant

26 April 2022

The European Research Council (ERC) is awarding grants to Roshan Cools and Peter Friedl, both professors at Radboudumc. While Cools will investigate how brains control behaviour in (stressful) situations, Friedl will work on developing a new cancer therapy.

read more

Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation published in Cellular and Molecular Life Sciences

20 April 2022 Lisa Huis in ‘t Veld, Nataschja Ho and colleagues from the team of Gosse Adema published in Cellular and Molecular Life Sciences that Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation. read more

Rubicon grants awarded to three RIMLS researchers

19 April 2022 Three researchers have received Rubicon funding from NWO/ZonMw. This will enable Elke Muntjewerff, Laura de Vries and Laurens van de Wiel to do research at a foreign research institute for the next two years. read more

ERC Proof of Concept Grant for Martijn Verdoes

8 March 2022 Martijn Verdoes, group leader Chemical Immunology at the department of Tumor Immunology, has been awarded an ERC Proof of Concept (PoC) Grant. The ERC PoC Grants are designed to support ERC grantees with the commercial or societal application of the results of their funded research. read more